What is the CONNECT Study?

The CONNECT study will test whether an oral, experimental drug, AZD0530 (saracatinib), will slow progression in mild-stage Alzheimer’s disease (AD). Although the cause of AD is unknown, several lines of evidence suggest that a peptide known as beta-amyloid plays a central role. Convergent evidence in recent years has yielded a refinement of the “amyloid hypothesis”, suggesting that neurotoxicity of beta-amyloid oligomers leads to Alzheimer’s disease. The protein Fyn kinase, a member of the Src family kinases, may play a fundamental role in the pathway by which beta-amyloid oligomers damage neurons. AZD0530 is a selective inhibitor of Src family kinases that was previously developed as a cancer therapy but may hold greater promise as a treatment for AD. CONNECT researchers will use PET imaging to evaluate whether the drug is effective in slowing decline in brain metabolism and will also determine whether it is safe and well tolerated in patients with AD. Screening will occur over six weeks followed by a 52-week treatment period. The study requires a minimum of four visits during the screening and 13 to 14 visits during the course of the treatment.

Researchers are looking for people who:
- Are 55-85 years of age
- Have a diagnosis of mild Alzheimer’s disease
- Are willing to undergo a variety of clinic assessments
- Have a study partner willing to attend clinic visits and have at least 10 hours/week of contact with study participant.

For more information on the CONNECT study please contact:

Barbara Martin
Sanders-Brown Center on Aging
University of Kentucky
(859)-323-0494
barbara.martin@uky.edu

This study is being conducted by the Alzheimer’s Disease Cooperative Study (ADCS) and Yale University through a grant from the National Center for Advancing Translational Sciences (NCATS), one of the National Institutes of Health.